profit from every $100 of sales.
$0$100
Hims & Hers Health
$19.73+0.00% today
-45.3% in 1 year
1-year low $14.521-year high $40.02
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $36.03 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Hims & Hers Health sold, what it kept, and what it did with the cash.
Sales went from $527 million in 2022 to $2.35 billion in 2025, with $128 million of profit last year.
SalesProfit
Hims & Hers Health handed back more cash to shareholders than it generated last year.
Buybacks $90M
Free cash flow 2025$57M
Bought back its own shares$90M
Paid as dividends–
Cash vs. debt$229M vs. $1.1B
Hims & Hers Health vs. similar companies
Hims & Hers Health grows in the middle of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Hims & Hers Health | 36.0× · Expensive | ||
 Concentra Group Holdings Parent | 32.1× · Expensive | ||
 Envista | 83.5× · Very expensive | ||
 Beta Bionics | No profit yet | ||
 CapsoVision | No profit yet |
AI analysis
An AI analyst reads Hims & Hers Health's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 149 | 272 | 527 | 872 | 1,477 | 2,348 | |
| 109 | 204 | 409 | 715 | 1,173 | 1,733 | |
| -15 | -115 | -69 | -29 | 62 | 106 | |
| -17 | -107 | -61 | -20 | 79 | 160 | |
| -18 | -108 | -66 | -24 | 126 | 128 | |
| -0.51 | -0.58 | -0.32 | -0.11 | 0.53 | 0.51 | |
| 73.6% | 75.2% | 77.6% | 82.0% | 79.5% | 73.8% | |
| -10.2% | -42.3% | -13.0% | -3.4% | 4.2% | 4.5% | |
| -12.2% | -39.6% | -12.5% | -2.7% | 8.5% | 5.5% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 119 | 421 | 366 | 441 | 708 | 2,155 |
| Cash | 27 | 72 | 47 | 97 | 221 | 229 |
| Total debt | – | – | 5 | 10 | 11 | 1,121 |
| Total liabilities | 16 | 86 | 55 | 97 | 231 | 1,614 |
| -147 | 335 | 312 | 344 | 477 | 541 | |
| 35 | 187 | 205 | 209 | 237 | 258 | |
| – | -26.2% | -17.1% | -6.6% | 10.0% | 5.0% | |
| 12.3% | -32.2% | -21.1% | -6.8% | 26.4% | 23.7% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| -2 | -34 | -27 | 73 | 251 | 300 | |
| – | – | 7 | 26 | 53 | 243 | |
| – | – | -34 | 47 | 198 | 57 | |
| Dividends paid | – | – | – | – | – | – |
| 0 | 0 | 0 | 2 | 83 | 90 | |
| 6 | 67 | 43 | 66 | 92 | 135 |
Valuation
- 36.0×
- 39.6×
- –
- 12.8×
- 2.0×
- 80.6×
- 34.5×
- 1.2%
- 2.8%
- 0.0%
Profitability
- 73.8%
- 4.5%
- 5.5%
- 4.2%
- 0.7%
- -5.2%
- -2.5%
- -0.6%
- 1.9%
- 7.0%
Growth
- +73.6%
- –
- −62.7%
- –
- +4.8%
Financial health
- 9.1×
- 2.54
- 49.9%
- –
- 1.69
- 1.55
- 1.05
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 38%of 946
Bottom 38%of 872
Bottom 37%of 563
Top 9%of 868
Top 50%of 986
What analysts expect
- Average price target
- $26.50
- Range
- $12.50 – $60.00
- 10 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | -0.18 | 0.04 | −550.0% |
| Feb 23, 2026 | 0.07 | 0.02 | +250.0% |
| Nov 3, 2025 | 0.06 | 0.09 | −33.3% |
| Aug 4, 2025 | 0.17 | 0.18 | −5.6% |
| May 5, 2025 | 0.20 | 0.12 | +65.4% |
| Feb 24, 2025 | 0.11 | 0.09 | +22.2% |
| Nov 4, 2024 | 0.06 | 0.06 | +0.0% |
| Aug 5, 2024 | 0.06 | 0.04 | +40.4% |
News
Should Hims & Hers Stock's Drop After Earnings Worry You?Yahoo Finance · Nov 13, 2026Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.MarketWatch · Nov 6, 2026Hims & Hers Health climbs 10% amid recent volatile tradingSeeking Alpha · Oct 9, 2026Hims & Hers Health facing penalties from Visa for credit card disputes - reportSeeking Alpha · Aug 21, 2026Hims & Hers CEO says FTC lawsuit misunderstands how the company worksCNBC · Aug 18, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
26No pass
Benjamin Graham
14No pass
Philip Fisher
42No pass
Peter Lynch
59No pass
Joel Greenblatt
4No pass
Charlie Munger
17No pass
Terry Smith
24No pass
Questions about Hims & Hers Health
Is Hims & Hers Health a good stock to buy?
A business with weak numbers, but the price is high. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Hims & Hers Health AI analysis
What does Hims & Hers Health do?
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. It is in Medical - Equipment & Services, based in San Francisco, CA, United States, with 2,442 employees.
Does Hims & Hers Health pay a dividend?
No. Hims & Hers Health does not pay a dividend at the moment; in 2025 it returned $90.0 million to shareholders by buying back its own shares.
Is Hims & Hers Health stock halal?
Yes. Hims & Hers Health passes our halal screen: its business is permitted and its debt is 24% of its market value, under the 30% limit. How we check
How has Hims & Hers Health stock done over the past year?
Down 45.3% over the past twelve months, to $19.73. It traded between $14.52 and $40.02 and is 50.7% below its high.
Who are Hims & Hers Health's competitors?
The largest listed companies in the same industry are Concentra Group Holdings Parent, Envista, Beta Bionics and CapsoVision. The peers table on this page compares their profit, growth and price with Hims & Hers Health's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.